Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST)

Abernethy A P, McCrory D C

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The aim of this review is to report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy, in particular on imatinib for gastrointestinal stromal tumors (GIST).

Project page URL
http://www.ahrq.gov/clinic/ta/gist/

Indexing Status
Subject indexing assigned by CRD

MeSH
Antineoplastic Agents; Gastrointestinal Stromal Tumors /drug therapy; Mouth Neoplasms /therapy; Pyrimidines

Language Published
English

Country of organisation
United States

Address for correspondence
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639; Email: AHRQTAP@ahrq.hhs.gov

AccessionNumber
32006000279

Date bibliographic record published
18/04/2006

Date abstract record published
18/04/2006